Myasthenia gravis is a rare chronic autoimmune disorder in which the immune system produces antibodies that prevent acetylcholine from binding with acetylcholine receptors, ultimately resulting in muscle contraction.

Interventions of Interest:

  • Efgartigimod (Argenx, Halozyme Therapeutics, and Zai Lab)
  • Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) 

For more information, please contact Maggie O’Grady, Program Manager, at

View the Key Stakeholder List.